SummaryThis is a non-randomised trial, including Part A (dose escalation) and Part B (dose expansion) treatment phases. In Part A, patients will be assigned to receive a standard (200mg) dose of Pembrolizumab followed by varying doses (A, B or C) of MK-4280 by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles. In Part B, patients will be assigned to groups based on their diagnosis. All patients will receive the standard dose (200mg) of Pembrolizumab followed by the recommended phase II dose of MK-4280 by infusion on Day 1 of each 3-week cycle for up to 35 cycles.
This trial is treating patients with Hodgkin Lymphoma, Non-Hodgkin Lymphoma or B-Cell Lymphoma.
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies